Human Cathepsin V Antibody

Detection of Cathepsin V by Western Blot

CTSV attenuates DOX-induced cellular senescence. (A). HUVECs were treated with ad-negative control (NC) or ad-CTSV (MOI = 10) for 8 h and simulated with 100 nM doxorubicin (DOX) and 1 μM RA for 24 h after incubated in complete growth medium for 40 h. SA-beta -gal activity was analyzed (blue staining for the senescent cells, scale bar = 50 μm, n = 4). (B) EdU assay of the cell proliferation ability in HUVECs treated with DOX, RA and ad-CTSV (red staining for the EdU, blue staining for Hoechst, scale bar = 25 μm, n = 4). (C) Representative image of the wound healing assay and the quantification of wound area in HUVECs (scale bar = 100 μm, n = 4). (D) Western blot of CTSV, ALDH1A2, P21, p-ERK1/2, ERK1/2, p-AKT, AKT, CTSL, P53, and P16 in HUVECs treated with DOX, RA and ad-CTSV (n = 4). (E) Relative mRNA level of CTSV, ALDH1A2, P21, IL-1 beta, IL-6, and ICAM-1 (n = 4). (F) RA concentration in HUVECs treated with DOX, RA, and ad-CTSV (n = 4). Data are presented as mean ± SEM. One-way ANOVA test was used. * p < 0.05, ** p < 0.01, *** p < 0.001. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36671735), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Cathepsin V by Western Blot

Inhibition of CTSV induces cellular senescence. (A) HUVECs were treated with si-negative control (NC), si-CTSV, si-ALDH1A2 or si-CTSV + si-ALDH1A2 for 24 h and simulated with 100 nM doxorubicin (DOX) for 24 h after incubated in complete growth medium for 24 h. SA-beta -gal activity was analyzed (blue staining for the senescent cells, scale bar = 50 μm, n = 4). (B) EdU assay of the cell proliferation ability in HUVECs treated with DOX, si-CTSV and si-ALDH1A2 (red staining for the EdU, blue staining for Hoechst, scale bar = 25 μm, n = 4). (C) Representative image of the wound healing assay and the quantification of wound area in HUVECs (scale bar = 100 μm, n = 4). (D) Western blot of CTSV, ALDH1A2, P21, p-ERK1/2, ERK1/2, p-AKT, AKT, CTSL, P53 and P16 in HUVECs treated with DOX and siRNAs (n = 4). (E) Relative mRNA level of CTSV, ALDH1A2, P21, IL-1 beta, IL-6 and ICAM-1 (n = 4). (F) RA concentration in HUVECs treated with DOX and siRNAs (n = 4). Data are presented as mean ± SEM. One-way ANOVA test was used. * p < 0.05, ** p < 0.01, *** p < 0.001. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36671735), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Cathepsin V by Western Blot

CTSV attenuates DOX-induced cellular senescence. (A). HUVECs were treated with ad-negative control (NC) or ad-CTSV (MOI = 10) for 8 h and simulated with 100 nM doxorubicin (DOX) and 1 μM RA for 24 h after incubated in complete growth medium for 40 h. SA-beta -gal activity was analyzed (blue staining for the senescent cells, scale bar = 50 μm, n = 4). (B) EdU assay of the cell proliferation ability in HUVECs treated with DOX, RA and ad-CTSV (red staining for the EdU, blue staining for Hoechst, scale bar = 25 μm, n = 4). (C) Representative image of the wound healing assay and the quantification of wound area in HUVECs (scale bar = 100 μm, n = 4). (D) Western blot of CTSV, ALDH1A2, P21, p-ERK1/2, ERK1/2, p-AKT, AKT, CTSL, P53, and P16 in HUVECs treated with DOX, RA and ad-CTSV (n = 4). (E) Relative mRNA level of CTSV, ALDH1A2, P21, IL-1 beta, IL-6, and ICAM-1 (n = 4). (F) RA concentration in HUVECs treated with DOX, RA, and ad-CTSV (n = 4). Data are presented as mean ± SEM. One-way ANOVA test was used. * p < 0.05, ** p < 0.01, *** p < 0.001. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36671735), licensed under a CC-BY license. Not internally tested by R&D Systems.